AI Article Synopsis

  • * Out of 141 patients analyzed, 76% of those free from diabetes at baseline experienced EPTH, leading to higher acute rejection rates and hospitalizations, as well as lower survival rates.
  • * Both EPTH and PTDM, along with pre-existing type 2 diabetes, significantly worsen patient outcomes, increasing hospitalization, rejection rates, and mortality risk compared to those who remain diabetes-free post-transplant.

Article Abstract

Aims: Early post-transplant hyperglycaemia (EPTH) and post-transplant diabetes mellitus (PTDM) are common following solid organ transplantation and may be associated with adverse outcomes. We studied the prevalence of EPTH and cumulative 5-year prevalence of PTDM in a modern cohort of heart transplant recipients who were free from diabetes at baseline as well as the association of EPTH, PTDM and pre-transplant T2DM with adverse transplant-related outcomes.

Methods: Retrospective cohort study of heart transplant recipients followed for 5 years at a single centre in Sydney, Australia.

Results: A total of 141 patients were included, of whom 25 had pre-existing type 2 diabetes mellitus (T2DM) and 116 were free from diabetes at baseline. In patients without pre-existing T2DM, 88 of 116 (76%) experienced EPTH, which was associated with higher rates of acute rejection and hospitalizations, and lower 5-year survival. PTDM developed in 45 of 116 (39%) patients, all of whom had experienced EPTH. Both PTDM and pre-existing T2DM were associated with increased rates of graft rejection and hospitalization, and greater than three-fold increased likelihood of death compared to patients that remained free from diabetes.

Conclusion: EPTH and PTDM are highly prevalent following cardiac transplantation. EPTH develops within days of transplant and is strongly associated with progression to PTDM. Pre-existing T2DM, PTDM and EPTH are associated with greater hospitalization, increased episodes of rejection and worse 5-year survival compared to patients who remained free from diabetes during follow-up.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635589PMC
http://dx.doi.org/10.1111/dme.15441DOI Listing

Publication Analysis

Top Keywords

diabetes mellitus
12
free diabetes
12
epth ptdm
12
pre-existing t2dm
12
early post-transplant
8
post-transplant hyperglycaemia
8
epth
8
ptdm
8
heart transplant
8
transplant recipients
8

Similar Publications

Protective Effect of Vitamin D Supplementation Against Atherosclerotic Cardiovascular Disease in Type 1 Diabetes Mellitus Model.

Endocr Metab Immune Disord Drug Targets

January 2025

Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, 24227, 20006, Saudi Arabia.

Introduction: Cardiovascular disease (CVD) is a leading cause of mortality on a global scale, with a higher prevalence observed among men. This study investigated the protective effect of vitamin D supplementation on CVD.

Methods: A cohort of thirty mice was divided into three groups: control, T1 diabetic, and T1 diabetic groups that received vitamin D treatment.

View Article and Find Full Text PDF

Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities.

Curr Med Chem

January 2025

Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey.

Introduction: Diabetes mellitus is associated with an increased risk of atherosclerosis related to dyslipidemia. Although the terms hyperlipidemia and Diabetes Mellitus [DM] or diabetic dyslipidemia are interrelated to each other, these two conditions have some differences.

Aim: This study aimed to highlight possible mechanisms of hyperlipidemia and/or dyslipidemia in diabetic patients, which can be treated with available and newer hypolipidemic drugs.

View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), also known as incretin mimetics, have significantly revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity worldwide, far exceeding initial expectations regarding their global prescription. This class of medications has demonstrated weight losses of up to 20 % of baseline body weight. Beyond their proven benefits in T2DM and obesity, GLP-1RAs, as well as dual and triple agonists (GLP-1/GIP/glucagon), are being investigated for their effects on conditions such as metabolic-associated steatotic liver disease, various cardiovascular disorders, neurocognitive impairments, and certain addictions.

View Article and Find Full Text PDF

Background: Diabetes mellitus and periodontitis are two common chronic diseases with bidirectional relationship. Considering the role of oxidative stress in the pathogenesis of these two diseases, the use of nutritional supplements with antioxidant properties can be useful. The purpose of this study was to determine the effectiveness of daily synbiotic supplement in the management of patients with type 2 diabetes mellitus (T2DM) and periodontal disease (PD) under non-surgical periodontal therapy (NSPT).

View Article and Find Full Text PDF

Background: Diabetes burnout represents a unique experience that shares some similarities with other psychological concepts. Differentiating diabetes burnout from depression symptoms is a challenging issue. This study aims to examine diabetes burnout profiles and their association with depression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!